![]() |
市場調查報告書
商品編碼
1468096
2024-2032 年按物種、抗毒液類型、作用方式、最終用戶和地區分類的抗毒液市場報告Anti-Venom Market Report by Species, Anti-venom Type, Mode of Action, End User, and Region 2024-2032 |
IMARC Group年,全球抗蛇毒血清市場規模達11.695億美元。蛇咬傷和蝎子蜇傷發生率的上升、政府有利舉措的實施以及行業的持續創新是推動市場發展的一些關鍵因素。
抗毒液,也稱為毒液抗血清,是指用於治療動物(包括蛇、蜘蛛、蝎子和某些海洋生物(例如水母或錐螺))毒咬傷或蜇傷的藥物。它是透過從犯罪動物身上提取毒液,然後將少量毒液注射到馬、綿羊或山羊等動物體內來獲得的,這些動物的免疫系統會產生抗體,這些抗體被收集和純化以產生抗毒液。抗蛇毒血清可以中和毒素並抵消毒液的影響,防止它們引起危及生命的併發症,例如呼吸衰竭或器官損傷。根據病史、檢查以及地理、臨床和病理因素,它在全球廣泛用於治療有毒咬傷和蜇傷。
世界各地,特別是農村和熱帶地區以及農業工人和獵人中的毒咬傷和蜇傷病例的增加,是推動市場成長的主要因素之一。除此之外,消費者對預防蛇咬傷的重要性以及以實惠的價格輕鬆獲得產品的重要性的認知不斷提高,正在為市場創造良好的前景。此外,政府實施的眾多打擊蛇咬傷舉措,例如教育和培訓計劃,以及對新型抗蛇毒產品研發(R&D)活動的大量投資,都有助於市場成長。除此之外,隨著對動物性蛋白質的需求不斷成長,面臨蛇咬傷風險的牲畜和其他動物數量增加,這反過來又為市場帶來了有利可圖的成長機會。同時,旅行和探索異國情調目的地(例如島嶼、沙漠、叢林和狩獵)的日益流行,使遊客面臨被蛇咬傷和遭遇其他有毒動物的風險,這是另一個重要的成長誘導因素。此外,生物技術和醫療保健行業的許多技術進步以及製造技術的持續創新改進,使得生產更有效和高效的抗蛇毒產品成為可能,對市場成長產生了積極影響。除此之外,各種快速蛇毒檢測試劑盒的推出正在推動市場的發展,這些試劑盒利用快速酵素免疫分析法,透過從咬傷部位、尿液、血漿、血液或其他組織和體液中採集的樣本來檢測和識別蛇毒。
The global anti-venom market size reached US$ 1,169.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,003.5 Million by 2032, exhibiting a growth rate (CAGR) of 6% during 2024-2032. The rising incidences of snake bites and scorpion stings, the implementation of favorable government initiatives, and ongoing innovations in the industry represent some of the key factors driving the market.
Anti-venom, also known as venom antiserum, refers to a type of medication used to treat the effects of venomous bites or stings from animals, including snakes, spiders, scorpions, and certain marine creatures such as jellyfish or cone snails. It is obtained by extracting venom from the offending animal and then injecting small amounts of the venom into animals, such as horses, sheep, or goats, whose immune systems produce antibodies that are harvested and purified to create anti-venom. Anti-venom neutralizes the toxins and counteracts the effects of the venom, preventing them from causing life-threatening complications such as respiratory failure or organ damage. It is extensively adopted across the globe in treating venomous bites and stings, depending on their history, examination, and geographic, clinical, and pathologic factors.
The rise in cases of venomous bites and stings across the world, particularly in rural and tropical regions and among agricultural workers and hunters, represents one of the prime factors driving the market growth. Besides this, the escalating consumer awareness of the importance of snake bite prevention and easy product availability at an affordable price is creating a favorable outlook for the market. Moreover, the implementation of numerous government initiatives to combat snake bites, such as education and training programs, and intensive investments in research and development (R&D) activities of new anti-venom products are contributing to the market growth. In addition to this, with the rising demand for animal-based protein, there is an increase in the number of livestock and other animals at risk of snake bites, which, in turn, is presenting remunerative growth opportunities for the market. Concurrent with this, the rising popularity of traveling and exploring exotic destinations, such as islands, deserts, jungles, and safaris, that puts tourists at risk of snake bites and other venomous animal encounters is acting as another significant growth-inducing factor. Furthermore, numerous technological advancements in the biotechnology and healthcare industries and ongoing innovative improvements in manufacturing technology, allowing for the production of more effective and efficient anti-venom products, are positively impacting the market growth. Apart from this, the launch of various rapid snake venom detection kits, which utilize a rapid enzyme immunoassay to detect and identify snake venom through samples taken from bite sites, urine, plasma, blood, or other tissues and body fluids, is propelling the market forward.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on species, anti-venom type, mode of action and end user.
Snake
Scorpion
Spider
Others
The report has provided a detailed breakup and analysis of the anti-venom market based on the species. This includes snake, scorpion, spider, and others. According to the report, snake represented the largest segment.
Polyvalent Anti-venom
Monovalent Anti-venom
A detailed breakup and analysis of the anti-venom market based on the anti-venom type has also been provided in the report. This includes polyvalent and monovalent anti-venom. According to the report, polyvalent anti-venom accounted for the largest market share.
Cytotoxic
Neurotoxic
Haemotoxic
Cardiotoxic
Myotoxic
Others
The report has provided a detailed breakup and analysis of the anti-venom market based on the mode of action. This includes cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. According to the report, neurotoxic represented the largest segment.
Hospitals
Clinics
Ambulatory Surgical Centers
A detailed breakup and analysis of the anti-venom market based on the end user has also been provided in the report. This includes hospitals, clinics, and ambulatory surgical centers. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-venom. Some of the factors driving the North America anti-venom market included the increasing incidence of snake bites, the introduction of numerous favorable government initiatives, and the thriving travel and tourism sector.
The report has also provided a comprehensive analysis of the competitive landscape in the global anti-venom market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.